Adicet bio announces first systemic sclerosis (ssc) patient dosed in ongoing phase 1 clinical trial of adi-001 in autoimmune diseases

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that the first systemic sclerosis (ssc) patient has been dosed in the second cohort of the phase 1 clinical trial evaluating adi-001 in autoimmune diseases. “we are pleased with the continued momentum of our phase 1 trial of adi-001 in autoimmune diseases as w.
ACET Ratings Summary
ACET Quant Ranking